Business
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
SAN DIEGO, March 03, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.
About this update from Contineum Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1875,"height":663,"url":"https://media.zenfs.com/en/business-wire.com/a4d799d21b63b6e35e954948657211b8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XPyf4C3ZW_Fn0kfyoAFxsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a4d799d21b63b6e35e954948657211b8","width":960,"height":339},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/W8DDXK.KwBFqVP7aYO6PVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a4d799d21b63b6e35e954948657211b8","width":1200,"height":424}},"lazy":false},{"type":"text","content":"SAN DIEGO, March 03, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.","length":437,"tagName":"p"},{"type":"text","content":"An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.","length":143,"tagName":"p"},{"type":"text","content":"About Contineum Therapeutics","length":28,"tagName":"p"},{"type":"text","content":"Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.","length":630,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260303064253/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","l...